Published in Gene Therapy Weekly, June 29th, 2006
The funds will be used for the continued clinical development of FoldRx's lead clinical candidate, Fx-1006A, and to advance its pipeline, which is initially focused on hereditary amyloidosis and neurodegenerative diseases, including Parkinson disease. Texas Pacific Group (TPG) Ventures and Alta Partners led the Series B round, which also included Novartis BioVenture Fund, as well as original investors, HealthCare Ventures and Fidelity Biosciences.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.